23 February 2022 - The MSAC Secretariat has published a list of applications scheduled to be considered by the ESC on 9 - 10 June 2022.

The agenda currently has 13 items. Applications of note include:

• 1408.1 – A prognostic RT-qPCR test for prediction of risk of distant recurrence of breast cancer under endocrine treatment
• 1658 – Testing of tumour tissue to determine a positive homologous recombination deficiency status in women newly diagnosed with advanced (FIGO stage III-IV) high grade epithelial ovarian, fallopian tube or primary peritoneal cancer for access to PBS olaparib
• 1668 – Whole body magnetic resonance imaging for detection of cancer in individuals with germline pathogenic TP53 variants
• 1686 – Lutetium Lu 177 PSMA for patients with metastatic castrate resistant prostate cancer
• 1690 – Ciltacabtagene autoleucel for the treatment of  patients with refractory or relapsed multiple myeloma
• 1697 – Review of different minimally invasive therapeutic approaches for the management of patients with benign prostatic hyperplasia

Read ESC agenda